W
William C. Knowler
Researcher at National Institutes of Health
Publications - 43
Citations - 8062
William C. Knowler is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 25, co-authored 43 publications receiving 7490 citations. Previous affiliations of William C. Knowler include American Indian Center.
Papers
More filters
Journal ArticleDOI
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
David M. Nathan,Beverly Balkau,Enzo Bonora,Knut Borch-Johnsen,John B. Buse,Stephen Colagiuri,Mayer B. Davidson,Ralph A. DeFronzo,Saul Genuth,Rury R. Holman,Linong Ji,Sue Kirkman,William C. Knowler,Desmond A. Schatz,Jonathan E. Shaw,Eugene Sobngwi,Michael Steffes,Olga Vaccaro,Nicholas J. Wareham,Bernard Zinman,Richard Kahn +20 more
TL;DR: Kilpatrick et al. as mentioned in this paper discussed the limitations of the A1C assay for populations in which it is not available or is currently too expensive, as well as for individuals in whom the assay may be misleading.
International expert committee report on the role of the A1C assay in the diagnosis of diabetes
David M. Nathan,Beverly Balkau,Enzo Bonora,Knut Borch-Johnsen,John B. Buse,Stephen Colagiuri,Mayer B. Davidson,Ralph A. DeFronzo,Saul Genuth,Rury R. Holman,Linong Ji,Sue Kirkman,William C. Knowler,Desmond A. Schatz,Jonathan E. Shaw,Eugene Sobngwi,Michael Steffes,Olga Vaccaro,Nicholas J. Wareham,Bernard Zinman,Richard Kahn +20 more
TL;DR: Members of the International Expert Committee have recommended that diabetes should be diagnosed if A1C is ≤6.5%, without need to measure the plasma glucose concentration, but there are concerns that practical limitations will lead to false positives and negatives with this approach.
Journal ArticleDOI
Diabetes mellitus in the pima indians: Incidence, risk factors and pathogenesis
Journal ArticleDOI
Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study
George A. Bray,Sharon L. Edelstein,Jill P. Crandall,Vanita R. Aroda,Paul W. Franks,Paul W. Franks,Wilfred Y. Fujimoto,Edward S. Horton,Susan Jeffries,Maria G. Montez,Sunder Mudaliar,F. Xavier Pi-Sunyer,Neil H. White,William C. Knowler +13 more
TL;DR: Metformin used for diabetes prevention is safe and well tolerated, and weight loss is related to adherence to metformin and is durable for at least 10 years of treatment.
Journal ArticleDOI
The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up
Vanita R. Aroda,Costas A. Christophi,Sharon L. Edelstein,Ping Zhang,William H. Herman,Elizabeth Barrett-Connor,Linda M. Delahanty,Maria G. Montez,Ronald T. Ackermann,X. Zhuo,William C. Knowler,Robert E. Ratner +11 more
TL;DR: In women with a history of GDM in the DPP/Diabetes Prevention Program Outcomes Study, both lifestyle and metformin were highly effective in reducing progression to diabetes during a 10-year follow-up period.